All Outputs (2)

HDAC inhibitor confers radiosensitivity to prostate stem-like cells (2013)
Journal Article
Frame, F. M., Pellacani, D., Collins, A. T., Simms, M. S., Mann, V. M., Jones, G., Meuth, M., Bristow, R. G., & Maitland, N. J. (2013). HDAC inhibitor confers radiosensitivity to prostate stem-like cells. The British Journal of Cancer, 109(12), 3023-3033. https://doi.org/10.1038/bjc.2013.691

Background:
Radiotherapy can be an effective treatment for prostate cancer, but radiorecurrent tumours do develop. Considering prostate cancer heterogeneity, we hypothesised that primitive stem-like cells may constitute the radiation-resistant fract... Read More about HDAC inhibitor confers radiosensitivity to prostate stem-like cells.

Differential cytotoxic activity of a novel palladium-based compound on prostate cell lines, primary prostate epithelial cells and prostate stem cells (2013)
Journal Article
Ulukaya, E., Frame, F. M., Cevatemre, B., Pellacani, D., Walker, H., Mann, V. M., Simms, M. S., Stower, M. J., Yilmaz, V. T., & Maitland, N. J. (2013). Differential cytotoxic activity of a novel palladium-based compound on prostate cell lines, primary prostate epithelial cells and prostate stem cells. PLoS ONE, 8(5), Article e64278. https://doi.org/10.1371/journal.pone.0064278

The outcome for patients with advanced metastatic and recurrent prostate cancer is still poor. Therefore, new chemotherapeutics are required, especially for killing cancer stem cells that are thought to be responsible for disease recurrence. In this... Read More about Differential cytotoxic activity of a novel palladium-based compound on prostate cell lines, primary prostate epithelial cells and prostate stem cells.